ABBV vs SKYE

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

Skye Bioscience remains a highly speculative, high-risk/high-reward opportunity with potential for 10x growth, contingent on overcoming severe financial challenges. The company validated its novel cannabinoid-derived therapeutic approach with positive top-line Phase 2a data for SBI-100 (glaucoma) in November 2024, demonstrating significant clinical de-risking and a substantial TAM. However, this c...